Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician

被引:96
作者
Rybak, MJ
McGrath, BJ
机构
[1] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT PHARM,DETROIT,MI
[2] ANTIINFECT RES LAB,DETROIT,MI
[3] GRACE HOSP,DEPT PHARM,DETROIT,MI
[4] WAYNE STATE UNIV,DETROIT,MI
关键词
D O I
10.2165/00003495-199652030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapy with antimicrobial combinations has been used as long as antimicrobials have been available. Combinations of antibiotics are often used to take advantage of different mechanisms of action and/or toxicity profiles. Well established indications for combination antimicrobial therapy include: (a) empirical treatment of life-threatening infections; (b) treatment of polymicrobial infections; (c) prevention of the emergence of bacterial resistance; and (d) for synergism. Disadvantages of combination therapy include: (a) increased expense; (b) increased risk of adverse effects; (c) antagonism; and (d) superinfection. Combination antimicrobial therapy should be considered for the treatment of serious Gram-negative infections caused by Enterobacter cloacae, Pseudomonas aeruginosa and Serratia marcescens, and certain Gram-positive infections caused by Enterococcus spp. and Staphylococcus spp. Selection of agents should be dependent upon local susceptibility patterns, clinical experience, site of infection, potential toxicities and cost.
引用
收藏
页码:390 / 405
页数:16
相关论文
共 109 条
[1]  
ABRAMOWICZ M, 1992, MED LETT, V34, P49
[2]   SINGLE OR COMBINATION THERAPY OF STAPHYLOCOCCAL ENDOCARDITIS IN INTRAVENOUS DRUG-ABUSERS [J].
ABRAMS, B ;
SKLAVER, A ;
HOFFMAN, T ;
GREENMAN, R .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (05) :789-791
[3]  
[Anonymous], PRINCIPLES PRACTICE
[4]   INFECTIOUS COMPLICATIONS OF NEOPLASTIC DISEASE [J].
ARMSTRONG, D ;
YOUNG, LS ;
MEYER, RD ;
BLEVINS, AH .
MEDICAL CLINICS OF NORTH AMERICA, 1971, 55 (03) :729-+
[5]   EVIDENCE FOR INVIVO INCORPORATION OF D-LACTATE INTO PEPTIDOGLYCAN PRECURSORS OF VANCOMYCIN-RESISTANT ENTEROCOCCI [J].
ARTHUR, M ;
MOLINAS, C ;
BUGG, TDH ;
WRIGHT, GD ;
WALSH, CT ;
COURVALIN, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :867-869
[6]  
ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1564
[7]   INFECTIVE ENDOCARDITIS [J].
BAYER, AS .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (03) :313-320
[8]  
BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
[9]   Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections [J].
Benko, AS ;
Cappelletty, DM ;
Kruse, JA ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :691-695
[10]   COST CONSIDERATIONS IN THERAPEUTIC DRUG-MONITORING OF AMINOGLYCOSIDES [J].
BERTINO, JS ;
RODVOLD, KA ;
DESTACHE, CJ .
CLINICAL PHARMACOKINETICS, 1994, 26 (01) :71-81